Model Informed Drug Development Archives

Blog

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…

Certara2026 年 1 月 26 日

Publication

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…

Certara2026 年 1 月 22 日

On-Demand Webinar

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…

Certara2026 年 1 月 22 日

Webinar

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Certara2026 年 1 月 14 日

On-Demand Webinar

监管前沿：全球战略洞察与 2026 展望，来自主要监管机构前任领导者的洞见

Watch this on-demand webinar featuring former regulators as they share global regulatory trends and clinical…

Certara2026 年 1 月 14 日

On-Demand Webinar

安全第一：揭示化合物筛选数据中的临床风险

Learn how to interpret screening assay data to predict clinical off-target risk with ToxStudio® and…

Certara2026 年 1 月 13 日

Publication

填补空白：Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development

Quantitative Systems Pharmacology (QSP) and Pharmacometrics (PMX) have historically existed at the two ends of…

Certara2026 年 1 月 7 日

Blog

Delivering on Deadline: Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions

Explore how PMx regulatory submissions, exposure-response modeling, and strategic pharmacometrics planning support successful and timely…

Certara2025 年 12 月 29 日

Fact Sheet

Strategic Project Management for Accelerated Drug Development

Expert project leadership to keep complex programs on track, aligned, and moving forward—so you can…

Certara2025 年 12 月 23 日

Conference

MVA Oncology Network

Certara2025 年 12 月 19 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

模型引导的药物开发

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

监管前沿：全球战略洞察与 2026 展望，来自主要监管机构前任领导者的洞见

安全第一：揭示化合物筛选数据中的临床风险

填补空白：Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development

Delivering on Deadline: Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions

Strategic Project Management for Accelerated Drug Development

MVA Oncology Network

订阅时事通讯

快捷链接

解决方案

联系我们